Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing
- 28 February 2007
- journal article
- case report
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 109 (2), 188-191
- https://doi.org/10.1016/j.clineuro.2006.07.003
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Use of Ziprasidone in Parkinsonian Patients With PsychosisClinical Neuropharmacology, 2005
- Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?Human Psychopharmacology: Clinical and Experimental, 2005
- Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic modelBrain, 2004
- Ziprasidone‐related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challengeHuman Psychopharmacology: Clinical and Experimental, 2004
- Ziprasidone in Parkinson's Disease PsychosisThe Canadian Journal of Psychiatry, 2004
- Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profileEuropean Journal of Pharmacology, 2001
- Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trialPsychopharmacology, 1998
- An Exploratory Haloperidol-Controlled Dose-Finding Study of Ziprasidone in Hospitalized Patients With Schizophrenia or Schizoaffective DisorderJournal of Clinical Psychopharmacology, 1998
- Fluoxetine improves emotional incontinenceBrain Injury, 1992
- Pathologic Laughing and Crying Treated With LevodopaArchives of Neurology, 1984